American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients
- PMID: 23664467
- DOI: 10.1016/j.ophtha.2013.03.012
American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients
Abstract
Purpose: To evaluate the clinical features and prognosis of posterior uveal (ciliary body and choroid) melanoma based on the American Joint Committee on Cancer (AJCC) classification (7th edition) of primary tumor (T).
Design: Retrospective, interventional case series.
Participants: Seven thousand seven hundred thirty-one patients.
Intervention: Ocular management including plaque radiotherapy, enucleation, local resection, or laser therapy.
Main outcome measures: Melanoma-related metastasis and death.
Results: Of 7731 patients with posterior uveal melanoma, the AJCC classification based on T was category T1 in 3557 (46%), T2 in 2082 (27%), T3 in 1599 (21%), and T4 in 493 (6%). Based on tumor categories T1, T2, T3, and T4, respectively, features that showed significant increase with tumor category included patient age at presentation (57, 58, 58, and 61 years; P<0.001), tumor base (8, 12, 15, and 20 mm; P<0.001), tumor thickness (3.5, 5.2, 8.9, and 11.4 mm; P<0.001), mushroom configuration (8%, 20%, 38%, and 39%; P<0.001), associated subretinal fluid (64%, 80%, 82%, and 83%; P<0.001), intraocular hemorrhage (5%, 12%, 17%, and 18%; P<0.001), rupture of Bruch's membrane (9%, 24%, 40%, and 40%; P<0.001), and extraocular extension (1%, <1%, 4%, and 12%; P<0.001). After therapy, Kaplan-Meier estimates of metastasis at 5, 10, and 20 years were 8%, 15%, and 25% for category T1, 14%, 25%, and 40% for category T2, 31%, 49%, and 62% for category T3, and 51%, 63%, and 69% for category T4, respectively (P<0.001). Kaplan-Meier estimates of death at 5, 10, and 20 years were 4%, 8%, and 11% for category T1, 8%, 13%, and 24% for category T2, 19%, 27%, and 36% for category T3, and 30%, 43%, and 51% for category T4, respectively (P<0.001). Compared with category T1, the hazard ratio for metastasis and death for T2 was 1.8 and 1.9, respectively, that for T3 was 4.5 and 4.7, respectively, and that for T4 was 8.2 and 8.8, respectively.
Conclusions: Based on the AJCC classification, increasing tumor category was associated with older age, larger tumor, and greater incidence of subretinal fluid, hemorrhage, and extraocular extension. Compared with uveal melanoma classified as T1, the rate of metastasis and death was 2 times greater for T2, 4 times greater for T3, and 8 times greater for T4. The risk for metastasis and death increased 2-fold with each increasing melanoma category.
Financial disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.Ophthalmology. 2018 Jun;125(6):913-923. doi: 10.1016/j.ophtha.2017.11.040. Epub 2018 Jan 17. Ophthalmology. 2018. PMID: 29342436
-
International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma.JAMA Ophthalmol. 2015 Apr;133(4):376-83. doi: 10.1001/jamaophthalmol.2014.5395. JAMA Ophthalmol. 2015. PMID: 25555246
-
American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture.Ophthalmology. 2015 Jun;122(6):1180-6. doi: 10.1016/j.ophtha.2015.01.026. Epub 2015 Mar 24. Ophthalmology. 2015. PMID: 25813452
-
Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture.Eye (Lond). 2015 Aug;29(8):1027-35. doi: 10.1038/eye.2015.51. Epub 2015 Aug 7. Eye (Lond). 2015. PMID: 26248525 Free PMC article. Review.
-
Prognostication of uveal melanoma is simple and highly predictive using The Cancer Genome Atlas (TCGA) classification: A review.Indian J Ophthalmol. 2019 Dec;67(12):1959-1963. doi: 10.4103/ijo.IJO_1589_19. Indian J Ophthalmol. 2019. PMID: 31755428 Free PMC article. Review.
Cited by
-
Uveal Melanoma in Ireland.Ocul Oncol Pathol. 2019 Apr;5(3):195-204. doi: 10.1159/000492391. Epub 2018 Sep 13. Ocul Oncol Pathol. 2019. PMID: 31049328 Free PMC article.
-
Posterior uveal melanoma in adolescents and children: current perspectives.Clin Ophthalmol. 2018 Nov 7;12:2205-2212. doi: 10.2147/OPTH.S142984. eCollection 2018. Clin Ophthalmol. 2018. PMID: 30464381 Free PMC article. Review.
-
Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel). 2024 May 2;14(9):958. doi: 10.3390/diagnostics14090958. Diagnostics (Basel). 2024. PMID: 38732371 Free PMC article. Review.
-
Ten-year outcomes of uveal melanoma based on The Cancer Genome Atlas (TCGA) classification in 1001 cases.Indian J Ophthalmol. 2021 Jul;69(7):1839-1845. doi: 10.4103/ijo.IJO_313_21. Indian J Ophthalmol. 2021. PMID: 34146040 Free PMC article.
-
Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives.Biomedicines. 2024 Aug 5;12(8):1758. doi: 10.3390/biomedicines12081758. Biomedicines. 2024. PMID: 39200222 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical